製品の概要

  • 製品名Anti-Ras antibody [F132-62]
    Ras 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [F132-62] to Ras
  • 特異性Reactive with the Ras translational products of the H-, K- and N-ras human, as well as mouse and rat c- and v-ras oncogenes.
  • アプリケーション適用あり: ICC/IF, IHC-Fr, IHC-P, WB, IP, ICC, Flow Cytmore details
  • 種交差性
    交差種: Mouse, Rat, Human
  • 免疫原

    Recombinant full length protein (Human).

  • ポジティブ・コントロール
    • Sw480 or Y1 cells or normal skin tissue.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab16907 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ICC/IF Use at an assay dependent concentration.
IHC-Fr Use a concentration of 5 µg/ml.
IHC-P Use a concentration of 5 µg/ml.
WB Use a concentration of 5 µg/ml. Predicted molecular weight: 23 kDa.
IP Use a concentration of 4 µg/ml.
ICC Use a concentration of 2 µg/ml.
Flow Cyt Use 1µg for 106 cells.

ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.

ターゲット情報

  • 機能Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • 関連疾患Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • 配列類似性Belongs to the small GTPase superfamily. Ras family.
  • 翻訳後修飾Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • 細胞内局在Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • C-BAS/HAS antibody
    • c-H-ras antibody
    • C-HA-RAS1 antibody
    • CTLO antibody
    • GTPase HRas antibody
    • GTPase KRas antibody
    • GTPase NRas antibody
    • H-Ras-1 antibody
    • H-RASIDX antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • HRAS antibody
    • HRAS1 antibody
    • K RAS2A antibody
    • K RAS2B antibody
    • K RAS4A antibody
    • K RAS4B antibody
    • K-RAS antibody
    • KRAS antibody
    • KRAS1 antibody
    • KRAS2 antibody
    • N-RAS antibody
    • N-terminally processed antibody
    • NRAS antibody
    • NRAS1 antibody
    • p21ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • RASK2 antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
    • v ras neuroblastoma RAS viral oncogene homolog antibody
    see all

Anti-Ras antibody [F132-62] 画像

  • Overlay histogram showing HeLa cells stained with ab16907 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab16907, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 100% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.

Anti-Ras antibody [F132-62] (ab16907) 使用論文

This product has been referenced in:
  • Li X  et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med N/A:N/A (2014). IHC-P ; Mouse . Read more (PubMed: 24859528) »
  • Marozkina NV  et al. S-nitrosoglutathione reductase in human lung cancer. Am J Respir Cell Mol Biol 46:63-70 (2012). WB ; Human . Read more (PubMed: 21816964) »

See all 3 Publications for this product

Product Wall

Thank you for contacting us.

We unfortunately do not have IHC tested image for this antibody so I am sorry we are unable to provide you this data.

We do however recommend using this antibody at 5ug/ml which is however for guidelines ...

Read More

Thank you for contacting us.
ab97488 and ab6548 are alternative to sc-520. Please note this assumption is based on the location of immunogen only. We might not have similar species or application data.
ab140962 and ab140377 are expected alter...

Read More

Thank you for contacting us. Because we carry over 100,000 products, it isn't feasible for us to keep small sample sizes of our products.

We are happy to reassure our customers that all of our products are covered by our Abpromise, which gua...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Specification HeLa
Fixative Paraformaldehyde
Blocking step Serum as blocking agent for 15 minute(s) · Concentration: 10%
Username

Abcam user community

Verified customer

投稿 Mar 30 2007

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"